Patents by Inventor Harold Walder

Harold Walder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210353954
    Abstract: A system and method for emitting a wavelength of energy internal to a medium or internal to a human or animal subject, and methods for using the system in the treatment of a condition, disorder, or disease. The system includes 1) a source configured to produce an initiation signal penetrating at least a part of the medium or the human or animal subject and 2) an insertion device having an electronics assembly unit. The assembly unit includes 1) an emitter configured to emit the wavelength of energy of a predetermined type to treat a disease or disorder in the human or animal subject or to produce a change in the medium and 2) a receiver that receives the signal.
    Type: Application
    Filed: July 29, 2021
    Publication date: November 18, 2021
    Applicant: IMMUNOLIGHT, LLC
    Inventors: Frederic A. BOURKE, JR., Harold WALDER, Zakaryae FATHI, Wayne F. BEYER, JR.
  • Patent number: 11135294
    Abstract: A method and system for treating a subject with a disorder which provides within the subject at least one photoactivatable drug for treatment of the subject, applies initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating at least one photoactivatable drug, and from the CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: October 5, 2021
    Assignees: IMMUNOLIGHT, LLC, DUKE UNIVERSITY
    Inventors: Mark Oldham, Justus Adamson, Mark W. Dewhirst, Paul Yoon, Harold Walder, Frederic A. Bourke, Jr., Zakaryae Fathi, Wayne F. Beyer, Jr.
  • Patent number: 11077316
    Abstract: A system and method for emitting a wavelength of energy internal to a medium or internal to a human or animal subject, and methods for using the system in the treatment of a condition, disorder, or disease. The system includes 1) a source configured to produce an initiation signal penetrating at least a part of the medium or the human or animal subject and 2) an insertion device having an electronics assembly unit. The assembly unit includes 1) an emitter configured to emit the wavelength of energy of a predetermined type to treat a disease or disorder in the human or animal subject or to produce a change in the medium and 2) a receiver that receives the signal.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: August 3, 2021
    Assignee: Immunolight, LLC
    Inventors: Frederic A. Bourke, Jr., Harold Walder, Zakaryae Fathi, Wayne F. Beyer, Jr.
  • Publication number: 20210145028
    Abstract: A method and a system for producing a change in a medium. The method places in a vicinity of the medium an energy modulation agent. The method applies an initiation energy to the medium. The initiation energy interacts with the energy modulation agent to directly or indirectly produce the change in the medium. The energy modulation agent has a normal predominant emission of radiation in a first wavelength range outside of a second wavelength range (WR2) known to produce the change, but under exposure to the applied initiation energy produces the change. The system includes an initiation energy source configured to apply an initiation energy to the medium to activate the energy modulation agent.
    Type: Application
    Filed: December 28, 2020
    Publication date: May 20, 2021
    Applicant: IMMUNOLIGHT, LLC
    Inventors: Frederic A. BOURKE, JR., Zakaryae Fathi, Harold Walder, Wayne F. Beyer, JR.
  • Patent number: 10940329
    Abstract: A phosphor-containing drug activator activatable from a Monte Carlo derived x-ray exposure for treatment of a diseased site. The activator includes an admixture or suspension of one or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays, wherein a distribution of the phosphors in the diseased target site is based on a Monte Carlo derived x-ray dose. A system for treating a disease in a subject in need thereof, includes the drug activator and a photoactivatable drug, one or more devices which infuse the photoactivatable drug and the activator including the pharmaceutically acceptable carrier into a diseased site in the subject; and an x-ray source which is controlled to deliver the Monte Carlo derived x-ray exposure to the subject for production of ultraviolet and visible light inside the subject to activate the photoactivatable drug.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: March 9, 2021
    Assignees: IMMUNOLIGHT, LLC, DUKE UNIVERSITY
    Inventors: Mark Oldham, Justus Adamson, Paul Yoon, Harold Walder, Frederic A. Bourke, Jr., Zakaryae Fathi, Wayne F. Beyer
  • Publication number: 20210035946
    Abstract: A polymerizable composition includes at least one monomer, a photoinitiator capable of initiating polymerization of the monomer when exposed to light, and a phosphor capable of producing light when exposed to radiation (typically X-rays). The material is particularly suitable for bonding components at ambient temperature in situations where the bond joint is not accessible to an external light source. An associated method includes: placing a polymerizable adhesive composition, including a photoinitiator and energy converting material, such as a down-converting phosphor, in contact with at least two components to be bonded to form an assembly; and, irradiating the assembly with radiation at a first wavelength, capable of conversion (down-conversion by the phosphor) to a second wavelength capable of activating the photoinitiator, to prepare items such as inkjet cartridges, wafer-to-wafer assemblies, semiconductors, integrated circuits, and the like.
    Type: Application
    Filed: August 17, 2020
    Publication date: February 4, 2021
    Applicant: Immunolight, LLC
    Inventors: Zakaryae FATHI, James CLAYTON, Harold WALDER, Frederic A. BOURKE, JR.
  • Patent number: 10874123
    Abstract: A method and a system for producing a change in a medium. The method places in a vicinity of the medium an energy modulation agent. The method applies an initiation energy to the medium. The initiation energy interacts with the energy modulation agent to directly or indirectly produce the change in the medium. The energy modulation agent has a normal predominant emission of radiation in a first wavelength range outside of a second wavelength range (WR2) known to produce the change, but under exposure to the applied initiation energy produces the change. The system includes an initiation energy source configured to apply an initiation energy to the medium to activate the energy modulation agent.
    Type: Grant
    Filed: March 2, 2020
    Date of Patent: December 29, 2020
    Assignee: IMMUNOLIGHT, LLC
    Inventors: Frederic A. Bourke, Jr., Zakaryae Fathi, Harold Walder, Wayne F. Beyer, Jr.
  • Publication number: 20200368547
    Abstract: A method for treating a disease, disorder, or condition in a subject in need thereof, by administering either or both of (i) at least one photoactivatable pharmaceutical agent, or (ii) a first plurality of energy-emitting particles, into the subject in a region of the disease, disorder, or condition, whereby the administering is performed through inhalation; and applying an applied electromagnetic energy to the subject, wherein the applied electromagnetic energy directly or indirectly activates the at least one photoactivatable pharmaceutical agent, when present, and wherein when the first plurality of energy-emitting particles is present, the first plurality of energy-emitting particles absorbs the applied energy and emits an emitted electromagnetic energy, wherein the emitted electromagnetic energy interacts directly with the region of the disease, disorder, or condition or activates the at least one photoactivatable pharmaceutical agent.
    Type: Application
    Filed: April 28, 2020
    Publication date: November 26, 2020
    Applicants: IMMUNOLIGHT, LLC., DUKE UNIVERSITY
    Inventors: Frederic A. BOURKE, JR., Harold WALDER, Zakaryae FATHI, Michael J. THERIEN, Mark W. DEWHIRST, Ian N. STANTON, Jennifer Ann AYRES, Diane Renee FELS, Joseph A. HERBERT
  • Publication number: 20200365552
    Abstract: A method of and system for adhesive bonding by a) providing a polymerizable adhesive composition on a surface of an element to be bonded to form an assembly; b) irradiating the assembly with radiation at a first wavelength capable of vulcanization of bonds in the polymerizable adhesive composition by activation of sulfur-containing compound with at least one selected from x-ray, e-beam, visible, or infrared light to thereby generate ultraviolet light in the polymerizable adhesive composition; and c) adhesively joining two or more components together by way of the polymerizable adhesive composition, and a curable polymer for use therein.
    Type: Application
    Filed: July 31, 2020
    Publication date: November 19, 2020
    Applicant: IMMUNOLIGHT, LLC
    Inventors: Zakaryae FATHI, Frederic A. BOURKE, JR., Harold WALDER
  • Publication number: 20200323711
    Abstract: A light emitting composition including first color emitters and second color emitters. The first color emitters are configured to emit, upon exposure to an energy source, visible light at a target color in response to absorption of energy across a first band of wavelengths. The second color emitters are configured to emit, upon exposure to the energy source, visible light at the target color in response to absorption of energy across a second band of wavelengths. The light intensity observable at the target color is enhanced relative to reflected white light without emission from the first and second color emitters. The light emitting composition can be a part of a paint, an ink, a fabric, a thread, a road sign, a highway marking, an automobile, a boat, a plane, a reflector, a building product, a concrete product, an epoxy product, a jewelry product, colored contact lens, a candle product, a rubber product, a plastic product, or other colored surface.
    Type: Application
    Filed: June 29, 2020
    Publication date: October 15, 2020
    Applicant: Immunolight, LLC
    Inventors: Frederic A. BOURKE, JR., Harold WALDER
  • Publication number: 20200282056
    Abstract: A phosphor-containing drug activator and suspension thereof are provided. The suspension at least includes two or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays. The two or more phosphors include Zn2SiO4:M12+ and (3Ca3 (PO4)2Ca(F, Cl)2:Sb3*, Mn2+) at a ratio NP-200:GTP-4300 of from 1:10 to 10:1, and each of the two phosphors have an ethylene cellulose coating and/or a diamond-like carbon coating. The suspension further includes a pharmaceutically acceptable carrier.
    Type: Application
    Filed: February 2, 2017
    Publication date: September 10, 2020
    Applicants: IMMUNOLIGHT, LLC, DUKE UNIVERSITY
    Inventors: Harold WALDER, Frederic A. BOURKE, JR., Zakaryae FATHI, Wayne BEYER, Mark OLDHAM, Justus ADAMSON, Michael NOLAN
  • Patent number: 10748868
    Abstract: A polymerizable composition includes at least one monomer, a photoinitiator capable of initiating polymerization of the monomer when exposed to light, and a phosphor capable of producing light when exposed to radiation (typically X-rays). The material is particularly suitable for bonding components at ambient temperature in situations where the bond joint is not accessible to an external light source. An associated method includes: placing a polymerizable adhesive composition, including a photoinitiator and energy converting material, such as a down-converting phosphor, in contact with at least two components to be bonded to form an assembly; and, irradiating the assembly with radiation at a first wavelength, capable of conversion (down-conversion by the phosphor) to a second wavelength capable of activating the photoinitiator, to prepare items such as inkjet cartridges, wafer-to-wafer assemblies, semiconductors, integrated circuits, and the like.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: August 18, 2020
    Assignee: IMMUNOLIGHT, LLC
    Inventors: Zakaryae Fathi, James Clayton, Harold Walder, Frederic A. Bourke, Jr.
  • Patent number: 10734353
    Abstract: A method of and system for adhesive bonding by a) providing a polymerizable adhesive composition on a surface of an element to be bonded to form an assembly; b) irradiating the assembly with radiation at a first wavelength capable of vulcanization of bonds in the polymerizable adhesive composition by activation of sulfur-containing compound with at least one selected from x-ray, e-beam, visible, or infrared light to thereby generate ultraviolet light in the polymerizable adhesive composition; and c) adhesively joining two or more components together by way of the polymerizable adhesive composition.
    Type: Grant
    Filed: July 18, 2019
    Date of Patent: August 4, 2020
    Assignee: Immunolight, LLC
    Inventors: Zakaryae Fathi, Frederic A. Bourke, Jr., Harold Walder
  • Publication number: 20200222711
    Abstract: A system and method for imaging or treating a disease in a human or animal body. The system provides to the human or animal body a pharmaceutical carrier including one or more phosphors which are capable of emitting ultraviolet or visible light into the body and which provide x-ray contrast. The system includes one or more devices which infuse a diseased site with a photoactivatable drug and the pharmaceutical carrier, an initiation energy source comprising an x-ray or high energy source which irradiates the diseased site with at least one of x-rays, gamma rays, or electrons to thereby initiate emission of said ultraviolet or visible light into the body, and a processor programmed to at least one of 1) produce images of the diseased site or 2) control a dose of said x-rays, gamma rays, or electrons to the diseased site for production of said ultraviolet or visible light at the diseased site to activate the photoactivatable drug.
    Type: Application
    Filed: December 27, 2019
    Publication date: July 16, 2020
    Applicants: IMMUNOLIGHT, LLC., DUKE UNIVERSITY
    Inventors: Harold WALDER, Frederic A. Bourke, JR., Zakaryae Fathi, Wayne F. Beyer, JR., Mark Dewhirst, Mark Oldham, Justus Adamson, Michael Nolan
  • Patent number: 10709900
    Abstract: A system and method for light stimulation within a medium. The system has a reduced-voltage x-ray source configured to generate x-rays from a peak applied cathode voltage at or below 105 kVp, and a plurality of energy-emitting particles in the medium which, upon radiation from the x-ray source, radiate at a first lower energy than the x-ray source to interact with least one photoactivatable agent in the medium. The method introduces the plurality of energy-emitting particles into the medium, radiates the energy-emitting particles in the medium with x-rays generated from a peak applied cathode voltage at or below 105 kVp; and emits a lower energy than the x-ray source to interact with the medium or with at least one photoactivatable agent in the medium.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: July 14, 2020
    Assignees: IMMUNOLIGHT, LLC., DUKE UNIVERSITY
    Inventors: Frederic A. Bourke, Jr., Harold Walder, Zakaryae Fathi, Michael J. Therien, Mark W. Dewhirst, Ian N. Stanton, Jennifer Ann Ayres, Diane Renee Fels, Joseph A. Herbert
  • Publication number: 20200215611
    Abstract: A curable resin or adhesive composition includes at least one monomer, a photoinitiator capable of initiating polymerization of the monomer when exposed to light, and at least one energy converting material, preferably a phosphor, capable of producing light when exposed to radiation (typically X-rays). The material is particularly suitable for bonding components at ambient temperature in situations where the bond joint is not accessible to an external light source.
    Type: Application
    Filed: March 16, 2020
    Publication date: July 9, 2020
    Applicant: IMMUNOLIGHT, LLC.
    Inventors: Zakaryae FATHI, James CLAYTON, Harold WALDER, Frederic A. BOURKE, JR.
  • Publication number: 20200196639
    Abstract: A method and a system for producing a change in a medium. The method places in a vicinity of the medium an energy modulation agent. The method applies an initiation energy to the medium. The initiation energy interacts with the energy modulation agent to directly or indirectly produce the change in the medium. The energy modulation agent has a normal predominant emission of radiation in a first wavelength range outside of a second wavelength range (WR2) known to produce the change, but under exposure to the applied initiation energy produces the change. The system includes an initiation energy source configured to apply an initiation energy to the medium to activate the energy modulation agent.
    Type: Application
    Filed: March 2, 2020
    Publication date: June 25, 2020
    Applicant: IMMUNOLIGHT, LLC.
    Inventors: Frederic A. BOURKE, JR., Zakaryae FATHI, Harold WALDER, Wayne F. BEYER, JR.
  • Publication number: 20200114164
    Abstract: Methods of treating a subject are provided, involving providing a first region of biological material coupled to the subject; initiating a change in a cellular environment of the cells in the first region; and due to a change in biological or chemical activity of the cells in the first region, inducing a biological change in a second region inside the subject, along with various biophoton collectors and biophoton bypasses useful for implementing a variety of the method embodiments.
    Type: Application
    Filed: October 11, 2019
    Publication date: April 16, 2020
    Applicant: IMMUNOLIGHT, LLC.
    Inventors: Frederic A. BOURKE, JR., Harold WALDER, Zakaryae FATHI, Wayne F. BEYER, JR., Ronald A. RUDDER
  • Patent number: 10596387
    Abstract: A system and method for imaging or treating a disease in a human or animal body. The system provides to the human or animal body a pharmaceutical carrier including one or more phosphors which are capable of emitting ultraviolet or visible light into the body and which provide x-ray contrast. The system includes one or more devices which infuse a diseased site with a photoactivatable drug and the pharmaceutical carrier, an initiation energy source comprising an x-ray or high energy source which irradiates the diseased site with at least one of x-rays, gamma rays, or electrons to thereby initiate emission of said ultraviolet or visible light into the body, and a processor programmed to at least one of 1) produce images of the diseased site or 2) control a dose of said x-rays, gamma rays, or electrons to the diseased site for production of said ultraviolet or visible light at the diseased site to activate the photoactivatable drug.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: March 24, 2020
    Assignees: IMMUNOLIGHT, LLC., DUKE UNIVERSITY
    Inventors: Harold Walder, Frederic A. Bourke, Zakaryae Fathi, Wayne F. Beyer, Mark W. Dewhirst, Mark Oldham, Justus Adamson, Michael Nolan
  • Patent number: 10593642
    Abstract: A curable resin or adhesive composition includes at least one monomer, a photoinitiator capable of initiating polymerization of the monomer when exposed to light, and at least one energy converting material, preferably a phosphor, capable of producing light when exposed to radiation (typically X-rays). The material is particularly suitable for bonding components at ambient temperature in situations where the bond joint is not accessible to an external light source.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: March 17, 2020
    Assignee: IMMUNOLIGHT, LLC.
    Inventors: Zakaryae Fathi, James Clayton, Harold Walder, Frederic A. Bourke, Jr.